This scientist is trying to stop a lab-created global disaster
By Kristen V. Brown,
Fusion
| 06. 27. 2016
When queried about the present state of biotechnology, Kevin Esvelt tends to sound more like a science skeptic than a pioneer of one of the most subversive genetic engineering technologies of all time.
“We are walking forwards blind,” Esvelt told me recently, chastising his field. “We are opening boxes without thinking about consequences. We are going to fall off the tightrope and lose the trust of public. Lots of people are going to die.”
Two years ago, Esvelt and his colleagues were the first to suggest that the gene-editing technology Crispr could be used to create what’s known as a gene drive, a formidable tool that can be used to override natural gene selection during reproduction to ensure that a desired trait is passed down throughout generations. Using gene drives, scientists could potentially alter the entire population of a species. It is a proposition that is at once both spectacular and terrifying.
Ever since putting the idea out there, Esvelt has been hard at work warning the world just how dangerous it might be. He worries that a lab...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
